Autres langues Ironwood Pharmaceuticals, Inc.

Actions

IRWD

US46333X1081

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 08/09/2026			Varia. 5j.	Varia. 1 janv.
4,170 ^USD	-2,11%		-2,34%	+23,74%

06/08	Transcript : Ironwood Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
06/08	Ironwood Pharmaceuticals, Inc. relève ses prévisions de résultats pour l'exercice 2026	CI

Autres langues

03/09	Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
07/08	Ironwood Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Ironwood Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2026
06/08	Ironwood: Q2 Earnings Snapshot
06/08	Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
30/07	Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
15/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development, STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
14/07	Ironwood Pharmaceuticals, Inc. Announces Management Changes
14/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
28/05	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
27/05	Ironwood Says US FDA Approves Linzess Use in Children Aged Two Years and Older With Functional Constipation
27/05	FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
27/05	Ironwood Pharmaceuticals Announces FDA Approval For Use Of LINZESS In Pediatric Patients Two Years Of Age And Older With Functional Constipation
13/05	Ironwood Pharmaceuticals CFO Gregory Martini Resigns
13/05	Ironwood Pharmaceuticals Inc - Gregory Martini resigns as CFO effective May 15, 2026 - SEC filing
13/05	Ironwood Pharmaceuticals, Inc. Announces Executive Changes, Effective May 15, 2026
13/05	Ironwood Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 15, 2026
08/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance
08/05	Ironwood Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Ironwood Pharmaceuticals : Q1 2026 Update
07/05	Earnings Flash (IRWD) Ironwood Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.24 per Share, vs. FactSet Est of $0.25
07/05	Earnings Flash (IRWD) Ironwood Pharmaceuticals, Inc. Reports Q1 Revenue $106.5M, vs. FactSet Est of $92.1M
07/05	Ironwood: Q1 Earnings Snapshot